← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Intratympanic golimumab for autoimmune inner ear disease
Also known as: Golimumab, Simponi, AIED, HRI-002, NCT01526174
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Biologic
Stage
Phase 1/2
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
82%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
United States
Population
adult, autoimmune-inner-ear-disease, sensorineural-hearing-loss, steroid-dependent
Trial IDs
1
Mechanism
TNF-alpha inhibitor delivered by intratympanic injection for autoimmune inner ear disease with progressive bilateral sensorineural hearing loss.
Indications
Notes
Corrected from a Janssen-owned program. ClinicalTrials.gov lists House Research Institute as lead sponsor and Janssen Services as collaborator. The trial was terminated because House Research was no longer conducting research.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...
IDs: NCT01526174, HRI-002
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyindustry-collaborator-not-primary-sponsorterminated-studyno-posted-results-confirmed
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2